29.03
0.97 (3.44%)
| Penutupan Terdahulu | 28.06 |
| Buka | 29.95 |
| Jumlah Dagangan | 41,180 |
| Purata Dagangan (3B) | 316,180 |
| Modal Pasaran | 1,432,256,000 |
| Harga / Jualan (P/S) | 4.79 |
| Harga / Buku (P/B) | 4.20 |
| Julat 52 Minggu |
| Margin Keuntungan | -6.48% |
| Margin Operasi (TTM) | -3.85% |
| EPS Cair (TTM) | -0.430 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 33.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 864.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 114.67% |
| Nisbah Semasa (MRQ) | 6.36 |
| Aliran Tunai Operasi (OCF TTM) | 31.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.36 M |
| Pulangan Atas Aset (ROA TTM) | -1.83% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Immunocore Holdings plc | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 5.18% |
| % Dimiliki oleh Institusi | 97.47% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 100.00 (HC Wainwright & Co., 244.53%) | Beli |
| Median | 60.50 (108.44%) | |
| Rendah | 33.00 (Mizuho, 13.70%) | Pegang |
| Purata | 62.50 (115.33%) | |
| Jumlah | 4 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 27.94 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Oppenheimer | 08 May 2025 | 86.00 (196.30%) | Beli | 29.79 |
| JP Morgan | 14 Apr 2025 | 50.00 (72.27%) | Beli | 26.92 |
| Needham | 10 Apr 2025 | 71.00 (144.62%) | Beli | 25.82 |
| 12 Mar 2025 | 71.00 (144.62%) | Beli | 29.05 | |
| Mizuho | 07 Apr 2025 | 33.00 (13.70%) | Pegang | 26.28 |
| HC Wainwright & Co. | 12 Mar 2025 | 100.00 (244.53%) | Beli | 29.05 |
| 05 Mar 2025 | 100.00 (244.53%) | Beli | 30.25 | |
| Morgan Stanley | 07 Mar 2025 | 35.00 (20.59%) | Pegang | 29.80 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 May 2025 | Pengumuman | Immunocore reports first quarter financial results and provides a business update |
| 02 Apr 2025 | Pengumuman | Immunocore to present at upcoming investor conferences |
| 10 Mar 2025 | Pengumuman | Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 |
| 03 Mar 2025 | Pengumuman | Immunocore to present at upcoming investor conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |